Company logo

HUM - Humana Inc.

NYSE -> Healthcare -> Healthcare Plans
Louisville, United States
Type: Equity

HUM price evolution
HUM
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Jan 2024
Current assets
Cash $5501 $5910 $4694
Short term investments $17424 $16697 $16626
Net receivables $4090 $3925 $2035
Inventory
Total current assets $32858 $32796 $29986
Long term investments $1124 $1110 $1122
Property, plant & equipment $2693 $2821 $2979 $3030
Goodwill & intangible assets $9567 $9563 $9550
Total noncurrent assets $17235 $17295 $17079
Total investments $18548 $17807 $17748
Total assets $50007 $50093 $50091 $47065
Current liabilities
Accounts payable $5915 $17973 $18233 $6569
Deferred revenue $313 $301 $266
Short long term debt $1504 $1155 $1796
Total current liabilities $7246 $19790 $19689 $8278
Long term debt $11886 $11746 $12390 $10213
Total noncurrent liabilities $13575 $14216 $11875
Total debt $13250 $13545 $12009
Total liabilities $32442 $33365 $33905 $30803
Shareholders' equity
Retained earnings $29118 $28745 $28173 $27540
Other shareholder equity -$653 -$1122 -$1086 -$999
Total shareholder equity $16671 $16130 $16262
(in millions $) 31 Jan 2024 31 Jan 2023 31 Dec 2021 31 Dec 2020
Current assets
Cash $4694 $5061 $3394 $4673
Short term investments $16626 $13881 $13192 $12554
Net receivables $2035 $1674 $1814 $1138
Inventory
Total current assets $29986 $26183 $24893 $23641
Long term investments $1122 $1129 $921 $2382
Property, plant & equipment $3030 $3221 $3073 $2371
Goodwill & intangible assets $9550 $9142 $11092 $4447
Total noncurrent assets $17079 $16872 $19465 $11328
Total investments $17748 $15010 $14113 $14936
Total assets $47065 $43055 $44358 $34969
Current liabilities
Accounts payable $6569 $5238 $12798 $12156
Deferred revenue $266 $286 $254 $318
Short long term debt $1796 $2390 $2279 $920
Total current liabilities $8278 $7914 $15331 $13394
Long term debt $10213 $9034 $10541 $6060
Total noncurrent liabilities $11875 $10507 $12924 $7847
Total debt $12009 $11424 $12820 $6980
Total liabilities $30803 $27744 $28255 $21241
Shareholders' equity
Retained earnings $27540 $25492 $23086 $20517
Other shareholder equity -$999 -$1304 $42 $391
Total shareholder equity $16262 $15311 $16080 $13728
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Jan 2024
Revenue
Total revenue $29397 $29540 $29611
Cost of revenue $25039 $25124
Gross Profit $4501 $4487
Operating activities
Research & development
Selling, general & administrative $3148 $3042
Total operating expenses $28614 $3360 $3251
Operating income $1141 $1236
Income from continuing operations
EBIT $1070 $1151
Income tax expense $155 $223 $251
Interest expense -$169 $168 $159
Net income
Net income $480 $679 $741
Income (for common shares) $679 $741
(in millions $) 31 Jan 2024 31 Dec 2022 31 Jan 2022 31 Dec 2020
Revenue
Total revenue $106374 $92870 $77155
Cost of revenue $75690 $61628
Gross Profit $17180 $15527
Operating activities
Research & development
Selling, general & administrative $12671 $10052
Total operating expenses $102361 $13380 $10541
Operating income $3800 $4986
Income from continuing operations
EBIT $3969 $4957
Income tax expense $836 $762 $1307
Interest expense -$493 $401 $283
Net income
Net income $2489 $2806 $3367
Income (for common shares) $2806 $3367
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Jan 2024
Net income $679 $741
Operating activities
Depreciation $243 $242
Business acquisitions & disposals -$3 -$14
Stock-based compensation $55 $45
Total cash flows from operations $1213 $423
Investing activities
Capital expenditures -$114 -$177
Investments -$885 -$223
Total cash flows from investing -$2889 -$1002 -$414 -$3492
Financing activities
Dividends paid -$323 -$107 -$109 -$431
Sale and purchase of stock -$49 -$717
Net borrowings -$265 $1563
Total cash flows from financing -$183 -$620 $1207 -$856
Effect of exchange rate
Change in cash and equivalents $422 -$409 $1216 -$367
(in millions $) 31 Jan 2024 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income $2806 $2933 $3367
Operating activities
Depreciation $845 $713 $616
Business acquisitions & disposals $2364 -$4187 -$709
Stock-based compensation $216 $180 $181
Total cash flows from operations $4587 $2262 $5639
Investing activities
Capital expenditures -$1120 -$1316 -$964
Investments -$2250 -$1053 -$1392
Total cash flows from investing -$3492 -$1006 -$6556 -$3065
Financing activities
Dividends paid -$431 -$392 -$354 -$323
Sale and purchase of stock -$2096 -$58 -$1771
Net borrowings -$1428 $3733 $1078
Total cash flows from financing -$856 -$1914 $3015 -$1955
Effect of exchange rate
Change in cash and equivalents -$367 $1667 -$1279 $619
News
UnitedHealth Falls on DOJ Probe Into Medicare Billing
Bloomberg · via Yahoo Finance 21 Feb 2025
Is Humana Inc. (HUM) the Best Non-Tech Stock to Buy Now for Long Term?
Insider Monkey · via Yahoo Finance 21 Feb 2025
We Think You Can Look Beyond Humana's (NYSE:HUM) Lackluster Earnings
Simply Wall St. · via Yahoo Finance 20 Feb 2025
UnitedHealth Pulls Back 11% in 3 Months: Think Twice Before Buying
Zacks · via Yahoo Finance 17 Feb 2025
Jim Cramer on Humana Inc. (HUM): ‘Medicare Provisions Were Much Better Than...
Insider Monkey · via Yahoo Finance 19 Jan 2025
Here's Why it is Prudent for Investors to Hold Humana Stock for Now
Zacks · via Yahoo Finance 17 Jan 2025
Will UNH, HUM & CVS be the Top Beneficiaries of the $21B MA Boom?
Zacks · via Yahoo Finance 16 Jan 2025
Company News for Jan 15, 2025
Zacks · via Yahoo Finance 15 Jan 2025
Humana Inc (NYSE:HUM): A Bullish Investment Perspective
Insider Monkey · via Yahoo Finance 14 Jan 2025
Big Gains Ahead for Medicare Advantage Sellers as Payments Set to Grow
Zacks · via Yahoo Finance 14 Jan 2025
Fundamentals
Market cap $30.56B
Enterprise value N/A
Shares outstanding 120.41M
Revenue N/A
EBITDA N/A
EBIT N/A
Net Income N/A
Revenue Q/Q 11.26%
Revenue Y/Y N/A
P/E ratio N/A
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio N/A
P/B ratio N/A
Book/Share N/A
Cash/Share N/A
EPS N/A
ROA N/A
ROE N/A
Debt/Equity 1.89
Net debt/EBITDA N/A
Current ratio N/A
Quick ratio N/A